Co-trimoxazole toxicity.

Lacey, R. W.; Hawkey, Peter M.; Devaraj, S.K.; Millar, M R; Inglis, Timothy J. J.; Godwin, P. G. R.

doi:10.1136/bmj.291.6493.481

Cited by 9 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Under the general note, CTX serves to be a safe medication and the drug is tolerated well. However, certain possible side-effects that are witnessed with the administration of drugs such as: gastrointestinal intolerance, vomiting, nausea, diarrhoea and anorexia [13]. Thus, the probable side effects are observed in the blood, such as hypokalaemia, also with a small upsurge on serum creatinine levels observed and hypernatremia.…”

Section: Co-tr Imoxazole: Phar Macological Char Acter Istics and Mechmentioning

confidence: 99%

Novel Delivery Approaches of Co-Trimoxazole for Recreating Its Potential Use-a Review

et al. 2021

View full text Add to dashboard Cite

Co-trimoxazole appropriates to category of broad-spectrum antimicrobial. They are active upon administration in vitro against an extensive collection of microorganisms. Their application in medical field has roughly spanned over decade now. There are numerous approaches that were progressed for improving their effectiveness towards their antimicrobial potency. However, routine use of this could accelerate the chance of bacterial resistance, and portrait it ineffective when required to treat infection. Consequently, newer investigations are necessary to keep the drug effective by minimise the development of resistance and maximise its safe use. Safe use is meant by safe delivery of drug in low dose, low frequency at the targeted molecule by effective ways. This can be achieved by using nanocarrier systems as they possess smart characteristics of effective drug delivery. These nanocarrier systems are including nanoparticle, liposomes, nanogels etc. Present review article deals with the historical perspectives with regards to co-trimoxazole, their mechanism of act/resistance and spectrum of activity in first section. In second portion different novel carriers, importance and application of nanogels, rational for co-trimoxazole nanogels are discussed. In conclusion, different literatures have proved the efficacy of nanogels in delivery of antimicrobial drug similar to co-trimoxazole. In the present time very less data is available for delivery of this drug with novel carriers. Therefore, this review aims to encourage researchers for creating some new findings in this perspective.

show abstract

Section: Co-tr Imoxazole: Phar Macological Char Acter Istics and Mechmentioning

confidence: 99%

Novel Delivery Approaches of Co-Trimoxazole for Recreating Its Potential Use-a Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…No change was made to the licensed indications, although there were calls for restrictions 18. However, by March 1986 the British National Formulary advised that co-trimoxazole be prescribed in older patients only if there was no acceptable alternative.…”

Section: Prescribing In Older Peoplementioning

confidence: 99%

Co-trimoxazole use restricted

1995

DTB

View full text Add to dashboard Cite

Co-trimoxazole, the fixed-dose preparation of trimethoprim (80mg) plus sulphamethoxazole (400mg), has been available in the UK since 1969. At its launch the Drug and Therapeutics Bulletin accepted the logic of using the combination1 but advised prescribers to be alert to the possibility of unwanted effects. In 1980 we advised that, in some infections, a single antibiotic might be at least as effective as co-trimoxazole, with a lower risk of unwanted effects.2 Later that year, when trimethoprim became available alone, we recommended it should be used in the place of co-trimoxazole for uncomplicated infections of the urinary tract,3 advice we repeated in 1986.4 In July of this year, the licensed indications for co-trimoxazole were narrowed5 and now reflect many of our earlier recommendations. In this article we review the history of co-trimoxazole, discuss the recent licensing changes and ask when the drug should be used in clinical practice.

show abstract

Adverse reactions to bactrim® — a retrospective view

Hell

1987

Infection

View full text Add to dashboard Cite

A historical survey based on the most important literature is presented as a starting point for further discussion on the significance of possible adverse reactions reported after prescription of cotrimoxazole. The often changing and contradictory assessments made of the situation in different countries and at different times are outlined, and the difficulty of making a balanced and just evaluation of long established drugs is shown, particularly if the available data are derived primarily from spontaneous reports which, besides being almost impossible to verify, are often incomplete.

show abstract

Co-trimoxazole toxicity.

Cited by 9 publications

References 10 publications

Novel Delivery Approaches of Co-Trimoxazole for Recreating Its Potential Use-a Review

Novel Delivery Approaches of Co-Trimoxazole for Recreating Its Potential Use-a Review

Co-trimoxazole use restricted

Adverse reactions to bactrim® — a retrospective view

Contact Info

Product

Resources

About